Lantern Pharma (NASDAQ: LTRN) announced it will host its first live, public demonstration of its withZeta.ai multi-agentic AI co-scientist platform on April 30, 2026, with two sessions scheduled to accommodate global audiences. The event will feature a real-time, interactive demonstration led by CEO Panna Sharma, showcasing the platform's ability to execute complex oncology research workflows by integrating clinical, molecular and scientific datasets.
Lantern said the platform is designed to accelerate drug discovery timelines, particularly in rare cancers, while supporting a scalable, subscription-based commercial model. The withZeta.ai platform is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. The company's clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
This demonstration is significant because it provides the biomedical community with a firsthand look at how AI can streamline oncology research, potentially reducing the time and cost of developing new therapies. For investors, the event underscores Lantern's transition from a pure drug developer to a provider of AI-driven research tools, opening up a new revenue stream through subscriptions. The platform's ability to integrate diverse datasets could also accelerate progress in rare cancers, where traditional drug development is often slow and expensive.
The company operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. For more details on the demonstration and to view the full press release, visit https://ibn.fm/wzevl. The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN.
